Navigation Links
YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Date:11/23/2009

edicted only by testing in humans. It is premature to select the best JAK2 inhibitors in clinical development as there is a need for longer follow-up data on safety and efficacy than is currently available. As such, the results of this study could yield important data on the potential for this molecule and possibly the entire class."

"Given the broad potential of JAK inhibitors, the human clinical safety data generated from this first clinical trial could be pivotal to the further development of CYT387 and its differentiation within the class. Limited data is available on the use of JAK 2 inhibitors in this patient population but a strong rationale exists to pursue this approach," said David Allan, Chairman and CEO of YM BioSciences. "This program has also been an opportunity for productive collaboration between the YM and Cytopia teams to further advance Cytopia's pipeline."

CYT387 is reported to potently inhibit the JAK2 enzyme, a mutated form of which has been implicated in a variety of MPNs including myelofibrosis, polycythemia vera and essential thrombocythemia. CYT387 has reportedly demonstrated the ability to attenuate MPN symptoms in preclinical models and disrupt JAK2 hyperactivity in cells from patients with MPNs. These data suggest that the compound may exert a profound effect on the human diseases. Over-activity of the JAK2 enzyme has also been noted in certain cancers and in inflammatory conditions, such as rheumatoid arthritis and psoriasis.

Myelofibrosis is a chronic, debilitating condition where the patient's bone marrow is replaced by scar tissue. This compromises the ability of patients to produce sufficient blood cells and creates a reliance on organs other than the bone marrow, including the liver and spleen, to produce blood cells. Typical symptoms include an enlarged spleen, progressive anemia and poor overall survival.

"The commencement of our CYT387 clinical study is another significant milestone de
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:2/27/2015)... Md. (PRWEB) February 27, 2015 ... Chromatography system (Nexera UC) can sequentially analyze up ... separation combined with high-sensitivity detection of targets by ... is designed to fulfill the measurement requirements of ... in food products, drug delivery and search for ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... CAMBRIDGE, Mass., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq: ... results for the third quarter of 2007 on Tuesday, ... In conjunction with the issuance of the press release, ... ET on Tuesday, November,6, 2007 to discuss the company,s ...
... tech development, opportunities for business growth, COLUMBUS, ... Ohio,colleges and universities increased academic research expenditures in ... than ever into high,technology R&D sectors throughout the ... high tech research, development and,commercialization, especially in the ...
... SAN FRANCISCO, Oct. 31 Medivation, Inc.,(Nasdaq: MDVN ... chief,executive officer, will present at the Acumen BioFin Rodman ... at 11:15 a.m. Eastern,Time at the New York Palace ... Medivation and its clinical,development programs for Dimebon(TM) for Alzheimer,s ...
Cached Biology Technology:Ohio Academic Institutions Increase Research and Development Investments 2Ohio Academic Institutions Increase Research and Development Investments 3Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Haven, Conn.Paleontologists have discovered a new species of dinosaur with ... skull, according to a paper published in the April issue ... species was a plant-eating dinosaur about as big as a ... said Nicholas Longrich of Yale University, lead author of the ...
... RIVERSIDE, Calif. Robert Luck , a professor of ... California Citrus Quality Council,s prestigious Albert G. Salter Memorial Award ... Luck is a leading expert in the research ... "This is a truly deserving award for Professor Luck ...
... The Marine Protected Areas Federal Advisory Committee will meet ... Charleston, S.C. The committee advises the Department of Commerce ... to the national system of MPAs. The ... includes integrating the national MPA system with the Coastal ...
Cached Biology News:New bony-skulled dinosaur species discovered in Texas 2UC Riverside entomologist recognized for research in citrus entomology 2
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
Request Info...
... The Cellject Uno Electroporator is ... for producing optimum efficiencies in bacterial ... simply selects one of two voltages ... or four mm cuvettes. On pressing ...
Request Info...
Biology Products: